Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.61+5.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GALT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Submit registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis with portal hypertension and advance clinical development.
Stated as a priority in 3 of last 3 quarters. Management reached agreement with FDA on key Phase 3 trial elements and plans to submit the protocol in Q3 2026. The company is advancing preparations and regulatory alignment, delivering on the stated timeline and regulatory path.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Reached agreement with FDA on key elements of planned Phase 3 trial and expect to submit protocol in Q3 2026.”
“Positive Type C meeting with FDA; plan to file Phase 3 protocol in Q3 2026.”
“Upcoming FDA meeting to align on next steps for advancing belapectin program in 2Q 2026.”
Ensure liquidity to support planned operations and research and development activities through at least June 2027.
Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents declined slightly from $14.1M in 2026-Q1 to $13.3M in 2026-Q2, with an additional $10M available under line of credit. Management consistently affirms sufficient liquidity to fund operations and R&D through mid-2027, delivering on this commitment.
“Company believes it has sufficient cash to fund operations and research and development activities through June 2027.”
“Company believes it has sufficient cash to fund operations and research and development activities through May 2027.”
“Company believes it has sufficient cash to fund operations and research and development activities through June 30, 2026.”
Convert outstanding convertible promissory notes into common stock to reduce debt and improve capital structure.
Newly stated in 2026-Q3 period (August 2026). Management executed conversion of $105.8 million in debt to equity, eliminating this debt and issuing 34.4 million shares, significantly strengthening the balance sheet. This is a one-time transformative capital structure event delivering on stated goals.
Present new analyses from NAVIGATE trial and publish manuscripts to support belapectin's clinical profile.
Stated as a priority in 2 of last 3 quarters. Management presented new analyses from the NAVIGATE trial at EASL 2026 and published manuscripts on trial results and endoscopy review methodology. This recurring focus shows progress in clinical data dissemination supporting belapectin's profile.
“New analyses presented at EASL and manuscripts published validating NAVIGATE trial data and central endoscopy review process.”
“Upcoming data presentations at EASL and further analyzing NAVIGATE dataset.”
Access a $10 million line of credit to finance working capital needs.
Over the trailing year it converted 0.78x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.